fda warning bpc-157 not approved for human use Regulatory Alert: The Legal Status of in Compounding and Clinical Practice – Holt Law bpc-157 fda warning not approved

Each published protocol follows a standardized 14-section format that includes a quick-reference card, titration schedule, reconstitution table with worked math, side effect profile with clinical trial percentages, clinical trial results summary, compound comparison table, and 1012 answered FAQs

Protocol Quick-Reference PRECLINICAL ONLY: NNMT inhibition research compound Dosing Amount No established human dose (mouse: ~34 mg/kg/day SC) Frequency No established human frequency Duration No established human duration Administration Route Oral Schedule N/A (preclinical compound) Timing NO HUMAN DOSING DATA EXISTS

Source : This study investigates the in vitro metabolism of four growth hormone-releasing hormone (GHRH) synthetic analogs, including sermorelin, in fortified urine for anti-doping purposes

Site: abdomen, thigh, upper arm, injury-adjacent tissue, or an IM muscle